Intravenous amantadine improves levadopa-induced dyskinesias: an acute double-blind placebo-controlled study.
about
Amantadine for dyskinesia in Parkinson's diseaseThe sigma-1 antagonist BMY-14802 inhibits L-DOPA-induced abnormal involuntary movements by a WAY-100635-sensitive mechanismDrug-induced dyskinesia in Parkinson's disease. Should success in clinical management be a function of improvement of motor repertoire rather than amplitude of dyskinesia?Eltoprazine counteracts l-DOPA-induced dyskinesias in Parkinson's disease: a dose-finding study.Pharmacogenetics of antipsychotic-induced movement disorders as a resource for better understanding Parkinson's disease modifier genesStriatal glutamate release in L-DOPA-induced dyskinetic animalsChronic 3,4-dihydroxyphenylalanine treatment induces dyskinesia in aphakia mice, a novel genetic model of Parkinson's disease.Intravenous amantadine for freezing of gait resistant to dopaminergic therapy: a randomized, double-blind, placebo-controlled, cross-over clinical trial.IRC-082451, a novel multitargeting molecule, reduces L-DOPA-induced dyskinesias in MPTP Parkinsonian primatesModification of brain aging and neurodegenerative disorders by genes, diet, and behavior.An updated meta-analysis of amantadine for treating dyskinesia in Parkinson's disease.A review of ropinirole prolonged release in Parkinson's disease.Allosteric modulators of NR2B-containing NMDA receptors: molecular mechanisms and therapeutic potentialMilestones in Parkinson's disease therapeutics.Motor complications in Parkinson's disease.Summary of the recommendations of the EFNS/MDS-ES review on therapeutic management of Parkinson's disease.Suitability of the adenosine antagonist istradefylline for the treatment of Parkinson's disease: pharmacokinetic and clinical considerations.Levodopa-induced dyskinesias in Parkinson's disease: emerging treatmentsNMDARs in neurological diseases: a potential therapeutic target.Pharmacological strategies for the management of levodopa-induced dyskinesia in patients with Parkinson's disease.Current and investigational non-dopaminergic agents for management of motor symptoms (including motor complications) in Parkinson's disease.Intravenous amantadine on freezing of gait in Parkinson's disease: a randomized controlled trial.MK-801 inhibits L-DOPA-induced abnormal involuntary movements only at doses that worsen parkinsonism.Clinical features, pathophysiology, and treatment of levodopa-induced dyskinesias in Parkinson's disease.Metabotropic glutamate receptors for Parkinson's disease therapy.NMDA receptor genotypes associated with the vulnerability to develop dyskinesiaAnti-dyskinetic mechanisms of amantadine and dextromethorphan in the 6-OHDA rat model of Parkinson's disease: role of NMDA vs. 5-HT1A receptorsA Case Report of Severe Delirium after Amantadine WithdrawalGlutamate NMDA receptor dysregulation in Parkinson's disease with dyskinesias.Possible role of nondopaminergic drugs on levodopa-induced dyskinesias in Parkinson's disease.Trial of dextromethorphan/quinidine to treat levodopa-induced dyskinesia in Parkinson's disease.Histamine H3 receptor agonists reduce L-dopa-induced chorea, but not dystonia, in the MPTP-lesioned nonhuman primate model of Parkinson's disease.Abnormal bidirectional plasticity-like effects in Parkinson's disease.[Pharmacological treatment of motor symptoms in Parkinson's diseases].Therapy for dyskinesias in Parkinson’s disease patientsLate (Complicated) Parkinson's Disease
P2860
Q24248660-B376B9D5-EA7F-4F87-A2D4-6DED00024BB8Q24614102-C8B67B6F-7205-4976-8FC6-38C3832F7FE2Q27021464-48167664-E2D6-4986-AFC5-EE000887D227Q27303857-DDE3C8B9-CF91-4E77-969B-3E3BB7D38BD5Q28088705-AFA83FB2-FA06-4729-AF9C-217883E51C1EQ28485942-C58A3549-E2AD-499D-9978-481B95244DFBQ30484170-2D414861-FBBE-4977-B874-DF82C79635D8Q34489770-A9CC459A-96D3-44EB-A955-04E129FBD20CQ34542164-DBF18AC9-0497-41DC-8DB2-9337DB904DA4Q34711201-51F01CF2-7DA3-4657-B30A-CC91DD5C0D24Q36376607-B10C464C-E57F-4FBE-A2D1-8FB90556E650Q37199938-A58008DB-4DC3-41FE-886B-2C4384C513D0Q37548763-4186CD98-65D7-4DA8-A73A-BED034F15866Q37882596-029938A6-1675-4AA5-8CFF-8794409D7464Q37950426-295681ED-9FA6-489A-A1BA-62612A52EDCBQ38070888-D1518863-3469-47CB-919E-269605BF704BQ38103966-92A116C7-E256-4238-96F4-76776BA0AF1CQ38156760-DBA4214F-41A8-4F69-B211-CEEC028F58F5Q38232734-01BC74B4-FFC6-4524-9DCE-DDE3D1201BD5Q38262418-56E33745-B1ED-4484-A57E-3DF9D95E4F84Q38636630-1167401C-BD0F-4CD5-A59A-66B205A02DB7Q39346402-3C47823D-5C53-49DE-A78F-1A1C5048CC21Q39906818-A16920F0-E5BA-43F0-810B-F89AD663ABDFQ41645312-5CC5DD38-5047-4681-8FE9-87DEDA7EA621Q41818450-AC3E725D-019E-4DAC-B761-080653EEF70EQ42072420-9EBC0FBD-2E7B-431D-A8D5-CA58661AEB6DQ42121362-FED65E60-F1DC-42AB-9867-D5AE7DB1A3FEQ42210942-B0963177-0703-40E1-B38D-5ED79696055DQ42747563-4E7BE2B9-CEFE-413F-B6FF-9AC3DE13A1FEQ43265625-9EF2D30B-BB2C-42C4-8B35-0C35066ECE44Q46280394-B97F619D-8BD5-4E57-B9DA-A403BB11C8B6Q46987576-A627A267-3F87-41E7-A11B-4441D400D6EDQ48829642-8A4178FB-CF0F-41C6-B06F-0A85896A1F9EQ52703430-80D1A931-49BA-4E4A-A08F-938DE596B30CQ57518128-2289D97B-0642-42F5-A199-63CBB727107DQ58870320-E5B333D3-722C-4D24-94F0-E16EC8561D71
P2860
Intravenous amantadine improves levadopa-induced dyskinesias: an acute double-blind placebo-controlled study.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
2001年學術文章
@zh
2001年學術文章
@zh-hant
name
Intravenous amantadine improve ...... lind placebo-controlled study.
@en
Intravenous amantadine improve ...... lind placebo-controlled study.
@nl
type
label
Intravenous amantadine improve ...... lind placebo-controlled study.
@en
Intravenous amantadine improve ...... lind placebo-controlled study.
@nl
prefLabel
Intravenous amantadine improve ...... lind placebo-controlled study.
@en
Intravenous amantadine improve ...... lind placebo-controlled study.
@nl
P2093
P356
P1433
P1476
Intravenous amantadine improve ...... blind placebo-controlled study
@en
P2093
G Gambaccini
L V Metman
P Del Dotto
S Bernardini
P304
P356
10.1002/MDS.1112
P407
P577
2001-05-01T00:00:00Z